RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost remission before stem cell transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that came back or didn't respond to initial therapy. First, participants receive tafasitamab (an antibody) plus lenalidomide, then a chemotherapy combo (ICE) plus tafasitamab. The goal is to see if this a…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo may bridge more patients to lifesaving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to keep the disease in check so more patients can qualify for and rec…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New Five-Drug cocktail shows promise for Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve complete …
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC